1. Stevelink R, Al-Toma D, Jansen FE, et al. Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis. EClinicalMedicine. 2022 Nov 11;53:101732. doi:10.1016/j.eclinm.2022.101732
  2. Campbell C, McCormack M, Patel S, et al. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia. 2022 Jun;63(6):1563-1570. doi: 10.1111/epi.17228
  3. Altmann A, Ryten M, Di Nunzio M, et al. A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies. Neuropathology and Applied Neurobiology. 2022;48(1):e12758. doi:10.1111/nan.12758
  4. Wolking S, Campbell C, Stapleton C, et al. Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.688386
  5. Wolking S, Schulz H, Nies AT, et al. Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics. 2020;21(5):325-335. doi:10.2217/pgs-2019-0179
  6. Wolking S, Moreau C, Nies AT, et al. Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia. 2020;61(4):657-666. doi:10.1111/epi.16467
  7. Wolking S, May P, Mei D, et al. Clinical spectrum of STX1B -related epileptic disorders. Neurology. Published online February 8, 2019:10.1212/WNL.0000000000007089. doi:10.1212/WNL.0000000000007089
  8. Silvennoinen K, de Lange N, Zagaglia S, et al. Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open. 2019;4(3):420-430. doi:10.1002/epi4.12349
  9. Lerche H, Sf B, Dh L, undefined. Intestinal-Cell Kinase and Juvenile Myoclonic Epilepsy. N Engl J Med. 2019;380(16):e24-e24. doi:10.1056/nejmc1805100
  10. Feng YCA, Howrigan DP, Abbott LE, et al. Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. The American Journal of Human Genetics. 2019;105(2):267-282. doi:10.1016/j.ajhg.2019.05.020
  11. McCormack M, Gui H, Ingason A, et al. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 2018;90(4):e332-e341. doi:10.1212/WNL.0000000000004853
  12. May P, Girard S, Harrer M, et al. Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. Lancet Neurol. 2018;17(8):699-708. doi:10.1016/S1474-4422(18)30215-1
  13. Berghuis B, Stapleton C, Sonsma ACM, et al. A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine. Epilepsia Open. 2018;0(ja). doi:10.1002/epi4.12297
  14. Androsova G, Krause R, Borghei M, et al. Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia. 2017;58(10):1734-1741. doi:10.1111/epi.13871
  15. Allen AS, Berkovic SF, Bridgers J, et al. Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data. European Journal of Human Genetics. 2017;25(7):894-899. doi:10.1038/ejhg.2017.61
  16. Leu C, Balestrini S, Maher B, et al. Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy. EBioMedicine. 2015;2(9):1063-1070. doi:10.1016/j.ebiom.2015.07.005